# Core B: Technology Development and Commercialization

> **NIH NIH P01** · CLEVELAND CLINIC LERNER COM-CWRU · 2020 · $150,575

## Abstract

ABSTRACT – CORE B
Cleveland Clinic has a long-standing commitment and documented success in transitioning laboratory
discoveries and clinical innovations into improvements in patient care. Core B was created for the TPPG Cycle
II in order to enhance and coordinate the outstanding Cleveland Clinic resources, and rapidly advance the
strong pipeline of early stage laboratory discoveries and technical innovations that have been generated in
Cycle I of the TPPG to commercialization. Core B will work in synergy with the project teams to validate and
transition the technologies by providing access to drug discovery and development resources, project
management support, and skills development. The Core will leverage the facilities available at Cleveland Clinic
Innovations (CCI), NIH Center for Accelerated Innovations at Cleveland Clinic (NCAI-CC) funded by NHLBI,
and the NSF funded Innovations-Corps Hub at Cleveland Clinic to promote the development of these
innovative projects through experienced project management and accelerated skills development. Core B will
facilitate the interactions with the established industry partners (Procter & Gamble, Nestle, Bayer, Ironwood,
Cleveland HeartLab, Wuxi, Novartis, and Johnson & Johnson) to insure rapid development of the projects. The
overall goal of Technology Development and Commercialization Core (Core B) of the TPPG is to
establish the needed organization to accelerate the current technologies from early-stage to
commercialization, and engage TPPG investigators to be full partners in transforming their discoveries
into high-impact advances in patient care. The Specific Aims include: To establish the resources necessary
for translating research into advanced solutions for improving asthma patient care (aim 1); To offer expert
project management guidance to the project teams (aim 2), and; To provide new and existing diverse
resources to educate and mentor our project researchers including basic, translational, and clinical scientists in
biomedical innovation and entrepreneurism (aim 3). All projects will utilize Core B resources.

## Key facts

- **NIH application ID:** 9986004
- **Project number:** 5P01HL103453-10
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** Ofer Reizes
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $150,575
- **Award type:** 5
- **Project period:** — → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9986004

## Citation

> US National Institutes of Health, RePORTER application 9986004, Core B: Technology Development and Commercialization (5P01HL103453-10). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9986004. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*